UNSPSC 51281806: Doxorubicin

This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80168379AG, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but generally known as doxorubicin, which bears US NIH Compound Identifier 1691. European Medicines Agency schedules Doxorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG.

UNSPSC 51281806 Doxorubicin is a Commodity code for oncology pharmaceuticals and related therapeutic agents. State and local governments procure doxorubicin and chemotherapy-class drugs through cooperative purchasing vehicles and direct contracts, typically as part of public health department inventory replenishment, correctional health services, or community health center supply chains. The code encompasses branded and generic formulations acquired in bulk quantities with extended shelf life and specific storage and handling requirements. Issuing bodies include state health departments, county public health agencies, and community health authorities that operate clinical or institutional pharmacy services.

Recent activity shows minimal direct doxorubicin procurement; instead, the recorded opportunities under this code reflect broader pharmaceutical warehouse and drug-supply contracts. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for a 12-month initial term with two renewal options, though the award covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride rather than doxorubicin specifically. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems, a procurement unrelated to the code's oncology-drug scope. The mismatch between the code's nominal focus and the recent opportunities suggests that doxorubicin procurement under this code is either infrequent or absorbed into broader pharmaceutical supply contracts that span multiple drug classes. Geographic activity appears concentrated in Florida and Illinois based on the recorded notices, though the limited sample size offers little signal for pipeline development.